- Remove All
- Your shopping cart is currently empty
EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $55 | Backorder | |
5 mg | $244 | Backorder | |
10 mg | $428 | Backorder | |
25 mg | $939 | Backorder |
Description | EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model. |
Alias | PEGFRvIII (9-mer), Epidermal Growth Factor Receptor Variant III Peptide |
Molecular Weight | 1079.20 |
Formula | C48H78N12O16.XCF3COOH |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | PBS pH 7.2: 10 mg/ml DMF: 10 mg/ml DMSO: 10 mg/ml |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.